TYME - TYME STOCK NEWS

TYME Technologies has released promising preclinical data on TYME-19, suggesting its effectiveness against SARS CoV-2 in human lung cells, achieving up to 90% viral mRNA inhibition following treatment. The company has completed necessary toxicity studies, paving the way for an Investigational New Drug (IND) application. TYME-19's unique mechanism of action may provide an alternative treatment option for COVID-19, particularly for patients facing unmet medical needs. This novel approach could be effective against various COVID-19 variants, enhancing treatment options.

TYME Technologies announced its abstract acceptance for presentation at the 2022 ASCO Gastrointestinal Cancers Symposium in January, showcasing Oral SM-88, a therapy showing promise in treating advanced pancreatic cancer. The presentation is part of their ongoing efforts to develop cancer metabolism-based therapies (CMBTs), targeting various solid tumors and hematologic cancers. CEO Richie Cunningham expressed excitement over the selection from over 750 submissions, highlighting the significance of their research in innovative gastrointestinal cancer treatments.

TYME Technologies announced significant advancements, including the first patient dosed in the Phase II OASIS trial for metastatic breast cancer, and plans to expand clinical trial sites for the PanCAN Precision Promise trial. The company reported a robust cash position of $96.6 million as of September 30, 2021, and a reduced operational cash burn rate of $5.0 million for Q2 FY 2022. With a net loss of $5.6 million or $0.03 per share, improvements in financial metrics were noted compared to the prior year, bolstering confidence in ongoing clinical efforts.

TYME Technologies, Inc. (Nasdaq: TYME), a biotechnology firm focused on cancer metabolism-based therapies (CMBTs™), will present at the Jefferies London Healthcare Conference on November 17, 2021, at 1:40 PM GMT / 8:40 AM EST. The presentation will be made by CEO Richie Cunningham and CBO Jonathan Eckard. A webcast of the event will be available on the Events & Presentations page of TYME’s website and archived for 90 days. TYME is developing its promising compound SM-88 for various advanced cancers, emphasizing its low toxicity and broad efficacy.

TYME Technologies, Inc. (NASDAQ: TYME) will report its second quarter fiscal 2022 financial results on November 8, 2021, at 8:30 AM ET. The call will be hosted by CEO Richie Cunningham and CFO Frank Porfido. A webcast of the event will be accessible on the company’s Investors page and archived for 90 days. Additionally, a Q&A session will follow the presentation, with questions accepted until 5:00 PM ET on November 4, 2021. TYME focuses on developing cancer metabolism-based therapies, particularly its compound SM-88.

TYME Technologies announced the first patient dosing in the Phase II OASIS trial, targeting metastatic HR+/HER2- breast cancer, a type representing 73% of breast cancer diagnoses. This trial evaluates oral SM-88, a drug demonstrating considerable anti-tumor activity in prior studies. The trial aims to determine the overall response rate in patients previously treated with CDK4/6 inhibitors, potentially expanding from 30 to 50 participants based on initial results. The trial underscores the urgency for effective cancer treatment options and TYME’s strategic focus on innovative therapies.

TYME Technologies, focusing on cancer metabolism-based therapies (CMBTs™), announced that CEO Richie Cunningham and CFO Frank Porfido will present at two upcoming healthcare conferences. The first is the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, accessible on-demand from 7:00 AM ET. The second is the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021, at 10:40 AM ET. Webcast links for both events are available. TYME’s emerging CMBT™ pipeline aims to target cancer's metabolic vulnerabilities.

TYME Technologies reported its fiscal first quarter ended June 30, 2021, highlighting key developments in its cancer therapies. The company has prioritized clinical trials in HR+/HER2- breast cancer, second-line pancreatic cancer, and sarcomas. A strategic review was completed, and a U.S. patent was granted for a new drug delivery method. The cash position decreased from $107.5 million to approximately $101.5 million, with a cash burn rate of $6.0 million, lower than previous projections. The net loss for the quarter was $5.9 million, an improvement from $8.8 million in the prior year.

TYME Technologies, an emerging biotechnology firm focused on cancer metabolism-based therapies, will announce its Q1 2022 financial results on August 10, 2021, at 8:30 AM ET. CEO Richie Cunningham and CFO Frank Porfido will lead a conference call and webcast, available on the TYME website. Participants can submit questions via email until 5:00 PM ET on August 6, 2021. The company aims to utilize unique therapeutic approaches targeting cancer cell metabolism, particularly through drug candidates TYME-18 and TYME-19, while also exploring treatments for viruses like COVID-19.